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Background: Oral iron supplementation is often associated with rapid onset of gastrointestinal side-effects. The aim
of this study was to develop and trial a short, simple questionnaire to capture these early side-effects and to
determine which symptoms are more discriminating.
Methods: The study was a double-blind placebo-controlled randomized parallel trial with one week treatment
followed by one week wash-out. Subjects were randomized into two treatment groups (n = 10/group) to receive
either ferrous sulphate (200 mg capsules containing 65 mg of iron) or placebo, both to be taken at mealtimes twice
daily during the treatment period. Subjects completed the questionnaires daily for 14 days. The questionnaire
included gastrointestinal symptoms commonly reported to be associated with the oral intake of ferrous iron salts
(i.e. nausea, vomiting, heartburn, abdominal pain, diarrhoea, and constipation).
Results: Seventy five per cent of participants reporting the presence of one or more symptoms in the first week of the
study were in the ferrous sulphate group. In the second week of the study (i.e. wash-out), 67% of the participants
reporting one or more symptom(s) were in the ferrous sulphate group. In the first week of the study (treatment) the
number of symptoms reported by participants in the ferrous sulphate group (mean ± SEM = 6.7 ± 1.7) was significantly
higher than that for participants in the placebo group (1.2 ± 0.5) (p = 0.01). In the second week of the study (wash-out)
the number of symptoms reported by participants in the ferrous sulphate group (4.6 ± 2.0) appeared higher than for
participants in the placebo group (1.0 ± 0.7) although this did not reach significance (p = 0.12). Events for which the
gastrointestinal symptom questionnaire was most discriminatory between ferrous sulphate and placebo groups were:
heartburn, abdominal pain and the presence of black stools (all p≤ 0.03).
Conclusions: A tool for the detection of commonly-occurring side effects should not require large study numbers to
be effective. With just 10 subjects per group (iron or placebo), this simple questionnaire measures gastrointestinal
side-effects associated with oral iron (ferrous sulphate) supplementation, and would be appropriate for use in
intervention studies or clinical trials.
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Despite many attempts to eradicate or even reduce iron de-
ficiency anaemia (IDA), it remains the most prevalent nutri-
tional deficiency disorder in the world affecting around 1.1
billion people of which nearly 400 million are children. The
World Health Organization (WHO) reports that world-
wide, at any given moment, more individuals have IDA
than any other health problem [1]. Iron deficiency anaemia
accounts for 2.4% of the global disease burden and it occu-
pies the World Health Organization (WHO) top ten hit list
of targeted global health problems [1-3].
One of the hurdles to eradicate this disorder has been
the use of iron preparations, typically ferrous iron salts 65
mgFe 2–3 times daily [4], that risk significant gastrointes-
tinal disturbances [5-10] and systemic infection [11-14].
Data from the National Health Service shows that at least
97.5% of the prescriptions filled for oral iron in England
alone are for simple ferrous salts (sulphate, fumarate or
gluconate) [15]. In the main, gastrointestinal side-effects
start to present early in the treatment course [7,16,17] al-
beit onset of symptoms and severity must be related to theFigure 1 One-page symptom questionnaire to assess gastrointestinal
‘J’ are not present on the actual questionnaire but are herein shown for eairon dosage and the posology followed (i.e. weekly or daily)
[18-23]. Reasons for gastrointestinal disturbance are well
described: even in subjects with IDA only about 20-30% of
oral supplemented iron is absorbed, while the remainder
transits through the gut lumen inducing (a) free radical
mediated damage to the gut mucosa [9,24-26] and (b) un-
desirable changes to colonic microflora [27-29]. Gastro-
intestinal symptoms impact on the general wellbeing of
individuals [30-37] and are known to affect compliance
with oral iron therapy and, therefore, treatment efficacy
[7,19,38-40].
Self-reporting questionnaires may be used to monitor
gastrointestinal symptoms in disease-specific scenarios
[35,41-44], although only a few have been formally tested
[36], but there is currently no gastrointestinal-specific
questionnaire to identify oral iron-induced symptoms in
healthy subjects [45]. The current study presents a simple
one-page gastrointestinal symptom questionnaire (a) to
capture the early side-effects normally associated with oral
iron (ferrous sulphate) supplementation and (b) to deter-
mine which symptoms are more discriminant. Sinceadverse effects after oral iron supplementation. The letters ‘A’ to
se of reference throughout this manuscript.
Table 1 Baseline socio-demographic data for the











Highest education level [n (%)]
GCSE 1 (10) 0
A level 2 (20) 4 (40)
First degree or professional qualification
4 (40) 3 (30)
Higher degree 3 (30) 3 (30)
Job title [n (%)]
Undergraduate student 4 (40) 3 (30)
PhD student 2 (20) 1 (10)
Secretary 1 (10) 0
Retired teacher 0 1 (10)
Dietician 3 (30) 2 (20)
Research fellow 0 2 (20)
Clinician 0 1 (10)
Differences were not significant between the 2 groups, with p > 0.05.
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http://www.biomedcentral.com/1471-230X/14/103gastrointestinal side effects, following oral iron, are report-
edly so common, any robust questionnaire should be valid
in just a small number of subjects. With just 10 subjects
per group (iron or placebo), this questionnaire is shown to
be a useful instrument to measure gastrointestinal side-
effects associated with oral iron supplementation, and




Questions for the gastrointestinal symptom questionnaire
(Figure 1) were based on previously validated bowel symp-
tom questionnaires [30,44,46,47] and included gastro-
intestinal symptoms commonly reported to be
associated with the oral intake of ferrous iron salts:
i.e. nausea, vomiting, heartburn, abdominal pain, diar-
rhoea, and constipation [5,19,48,49]. In addition, the
questionnaire included questions on breathlessness be-
cause this is common in anaemic patients and head-
ache that, although not generally associated with oral
iron therapy, is common with some gastrointestinal
complaints [50,51].
The degree of discomfort from each symptom was
ranked by the study subjects in one of four categories(absent, mild, moderate or severe) as used in previous
studies [44,52]. The frequency of bowel movements
was registered and the questionnaire included a ques-
tion on whether these were normal or abnormal. Com-
pliance with the oral iron or placebo treatment was
also assessed.
Participants
Twenty healthy subjects, seven men and thirteen
women aged 18–65 years (average age 32), were re-
cruited via circular email. The presence of any chronic dis-
ease, pregnancy or lactation were considered as exclusion
criteria. Subjects were asked to complete a baseline ques-
tionnaire including demographic questions on age, gender,
education and job title.
This study was conducted according to the guidelines laid
down in the Declaration of Helsinki and all procedures in-
volving human subjects were approved by the King’s College
London (KCL) Research Ethics Committee and treatment
capsules were approved by the U.K. Medicines and Health-
care Products Regulatory Agency (MHRA). Written in-
formed consent was obtained from all subjects.
Study design
The study was a double-blind placebo-controlled ran-
domized parallel trial with one week treatment followed
by one week wash-out. Subjects were randomizsed into
two treatment groups (n = 10/group) to receive either fer-
rous sulphate (200 mg capsules containing 65 mg of iron)
or placebo, both to be taken at mealtimes twice daily for
7 days during the treatment period. All subjects were ad-
vised that they may suffer black stools, as a normal conse-
quence of intervention, irrespective of whether they were
on placebo or oral iron (although placebo had no specific
stool-darkener added).
Subjects were provided with two seven-day symptom
questionnaires (Figure 1) to take home for self-completion,
and asked to complete them on a daily basis for 14 days –
the first 7 days whilst on one of the treatments (i.e. ferrous
sulphate or placebo) and the following 7 days during the re-
spective wash-out periods. The symptom diaries were coded
and anonymised. Codes were broken only after the raw
questionnaire data had been entered into the database.
Data analysis
The questionnaire is broken down into different compart-
ments (boxes ‘A’-‘J’) for ease of reference in this manuscript
(Figure 1). Although all data were collected, only those
from boxes C, H,I and J were analysed and are herein re-
ported in figures, tables and/or text. All statistical analysis
was performed using GraphPad Prism version 5.03 for
Windows (GraphPad Software, San Diego, California,
USA). Results are presented as means with either standard
error of mean (SEM) or standard deviation (SD) as
Figure 2 Mean (SEM) incidence per participant of symptoms,
from ‘box C’ of the questionnaire, in in week 1 (treatment) and
week 2 (wash-out) of the iron and placebo groups. The mean
incidence of symptoms for the week as mild (stripped part of
columns), moderate (closed) and severe (open) is shown.
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treatment and wash-out periods and between ferrous
sulphate and placebo were examined using the unpaired t-
test (two-tailed) with Welch’s correction for non-equal vari-
ances (level of significance set to p < 0.05). Where, for theTable 2 Frequency of individual symptoms irrespective of wh
Iron
Symptom Treatment Wash-ou
Nausea 1.1 ± 0.6 0.1 ± 0.1
(−0.3; 2.5) (−0.1; 0.3
Heartburn 1.0 ± 0.4 0.3 ± 0.3
(0.1; 1.9) (−0.4; 1.0
Abdominal pain 2.0 ± 0.6 1.0 ± 0.7
(0.5; 3.5) (−0.7; 2.7
Headache 1.1 ± 0.5 1.6 ± 0.6
(−0.1; 2.3) (0.2; 3.0)
Breathlessness 0.1 ± 0.1 0.5 ± 0.3
(−0.1; 0.3) (−0.3; 1.3
Diarrohea 0.4 ± 0.3 0.3 ± 0.2
(−0.3; 1.1) (−0.2; 0.8
Constipation 1.0 ± 0.6 0.7 ± 0.5
(−0.3; 2.3) (−0.4; 1.8
Change bowel movements 1.3 ± 0.5 1.5 ± 0.3
(0.1; 2.5) (0.7; 2.3)
Black stools 4.1 ± 0.7 1.3 ± 0.4
(2.4; 5.8) (0.4; 2.2)
p = 0.002
Values, derived from boxes ‘C’ and ‘H’ of the questionnaire (Figure 1), are shown as
#significance value (p < 0.05) between the frequency of each symptom for the Ironplacebo group, there was an absence of an individual symp-
tom (i.e. for heartburn, breathlessness or black stools) com-
parisons with the ferrous sulphate group were made using
the paired t-test (two-tailed). The number of black stool
movements on each day was compared using the one-way
analysis of variance with the Bonferroni post-hoc test to
correct for multiple comparisons.
Results and discussion
Twenty healthy subjects (10/group) took part in the study.
The two study groups were similar in terms of socio-
demographic characteristics, age and gender (Table 1). Par-
ticipants were randomly allocated to the 2 groups (ferrous
sulphate or placebo) and asked to complete the gastrointes-
tinal symptom questionnaire every day for 14 days. The
completion rate of the symptom questionnaire was 100%.
All participants found the symptom questionnaire easy to
complete but some suggested that a ‘comments’ section be
included so that they could, at times, provide reasons for
responses. The average time for completion of the ques-
tionnaire was less than 5 minutes per day. Compliance
with oral iron/placebo was >80% for the morning dose
and >90% for the evening dose for participants in both
groups and did not differ between groups. Reasons pro-
vided for non-compliance were unrelated to the study
treatments.ether mild, moderate or severe (days per week)
Placebo
t Treatment Wash-out p value#
0.2 ± 0.1 0.4 ± 0.4 0.2
) (−0.1; 0.5) (−0.5; 1.3)
0 0 0.03
) (0; 0) (0; 0)
0.2 ± 0.1 0 0.02
) (−0.1; 0.5) (0; 0)
0.2 ± 0.2 0.1 ± 0.1 0.15
(−0.3; 0.7) (−0.1; 0.3)
0 0.1 ± 0.1 0.3
) (0; 0) (−0.1; 0.3)
0.3 ± 0.3 0.4 ± 0.2 0.8
) (−0.4; 1.0) (−0.1; 0.9)
0.2 ± 0.2 0 0.2
) (−0.3; 0.7) (0; 0)
0.4 ± 0.3 0.4 ± 0.2 0.15
(−0.2; 1.0) (−0.1; 0.9)
0 0 0.0004
(0; 0) (0; 0)
mean ± standard error (95% confidence interval) for the two groups.
treatment period versus the Placebo treatment period.
Figure 3 Incidence of individual symptoms in the iron and
placebo groups. A, percentage of participants in each group
reporting nausea, heartburn, abdominal pain (ABD pain),
constipation, change in bowel movements (Bowel mov) or the
presence of black stool movements on at least one day of each
week of the intervention or wash-out periods (i.e. data from boxes
‘C’ and ‘H’ on the questionnaire (Figure 1)). The number of participants
reporting symptoms in the iron group was significantly higher than
that of the placebo group (p = 0.01). B, mean number of black bowel
movements per day, obtained from box ‘H’ of the questionnaire (Figure 1),
in the iron group (no black bowel movements were reported in the
placebo group). Error bars represent standard error of mean (SEM).
*p < 0.05; **p < 0.01 for comparison between each treatment day and
the baseline (i.e. day 0). ##p < 0.01 for comparison between each
wash-out day and the end of the treatment period (i.e. day 7).
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ported the presence of one or more symptom(s) in the
first week of the study (i.e. during treatment), of which 9
(75%) were in the ferrous sulphate group. In the second
week of the study (i.e. wash-out), 9 participants reported
one or more symptom(s), of which 6 (67%) were in the fer-
rous sulphate group. The degree of discomfort caused by
each symptom was categorised into mild, moderate or se-
vere as defined in box ‘C’ of the questionnaire (Figure 1).
Detailed analyses were as follows: in the first week of the
study (treatment) the number of symptoms reported per
participant in the ferrous sulphate group (mean = 6.7,
SEM= 1.7) was significantly higher than that reported per
participant in the placebo group (mean = 1.2, SEM= 0.5)
(p = 0.01). In the second week of the study (wash-out) the
number of symptoms reported per participant in the fer-
rous sulphate group (mean = 4.6, SEM= 2.0) tended to be
higher than that per participant in the placebo group
(mean = 1.0, SEM= 0.7) but this did not reach significance
(p = 0.12) (Figure 2).
Table 2 shows the reported frequency for individual
symptoms by the participants in the ferrous sulphate and
placebo groups during the treatment and wash-out periods.
Adverse events for which the gastrointestinal symptom
questionnaire was most discriminatory between ferrous
sulphate and placebo groups were: heartburn, abdominal
pain and the presence of black stools (all p ≤ 0.03) (Table 2).
The differences observed in nausea, constipation and
change in bowel movements between the ferrous sulphate
and placebo groups may be clinically significant but, due to
the small sample size, did not reach statistical significance
(Table 2). The number of participants in each group report-
ing these individual symptoms is presented in Figure 3A,
for both treatment and wash-out weeks. Vomiting was not
reported by participants in either group on any day. Overall,
the number of participants reporting symptoms in the iron
group was significantly higher than the number of partici-
pants reporting symptoms in the placebo group (p = 0.01).
The nature of the symptoms reported in the oral iron
group is not surprising as iron that remains soluble in the
intestinal lumen is likely to be bioavailable but, equally,
may be available for other processes including uptake by
commensal flora and colonic epithelial cells, and facile
redox-cycling in the gut lumen. Indeed, the generation of
harmful free-radicals through Fenton chemistry which can
cause inflammation and oxidative stress in the intestinal
mucosa has been linked to available luminal iron in several
studies [53-55]. Furthermore, detrimental changes to the
commensal microbiota have recently been reported with
oral iron supplementation and may be partly responsible
for the distal symptoms such as constipation and diarrhoea
[27-29,56].
Figure 3B shows the number of black stool movements
reported in the ferrous sulphate group: no black stoolswere reported by participants in the placebo group. For
those participants taking ferrous sulphate there was a sig-
nificant increase in the number of black stool movements
from day 3 of the treatment period (p = 0.03) which only
returned to baseline 3 days after stopping the ferrous
sulphate tablets (i.e. day 10 of the study) (p = 0.005)
(Figure 3B). Although subjects were not aware of which
group they were in (i.e. treatment or placebo), the pres-
ence of black stools could have provided an indication
of their randomisation to oral iron. It is thus important
to note that symptoms were being reported in the fer-
rous sulphate group from the first day (for example
nausea and abdominal pain) and this was before the on-
set of black stools which was significant at 72 hours.
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tion is derived from the reaction of hydrogen sulphide pro-
duced by commensal bacteria, such as sulphate-reducing
bacteria, with ferrous iron (Fe2+) to produce iron sulphide
(FeS). Sulphate-reducing bacteria are a group of ‘emerging
pathogens’ in the colon. These bacteria have an exception-
ally high requirement for iron and use sulphur or sulphate,
which are plentiful in the colon from the digestion of foods,
as electron acceptors during anaerobic respiration, for the
oxidative metabolism of organic compounds and H2 [57].
Indeed, Werner et al. have shown that numbers of Desulfo-
vibrio (the main sulphate-reducing bacteria found in faeces)
significantly increased following ferrous sulphate supple-
mentation [28].
Conclusions
A short and simple-to-answer gastrointestinal symptom
questionnaire was developed as a tool to measure adverse-
effects for use in intervention studies with oral iron and
especially when ferrous sulphate comprises one study arm.
The present small study aimed to show where the ques-
tionnaire had discriminatory power: i.e. which symptoms
are more sensitive to oral ferrous sulphate therapy. The
questionnaire was filled in by the study participants during
the 7-days of the treatment period and the 7-days of the
wash-out period and was discriminant in the total number
of reported symptoms per participant between the iron
and the placebo groups. Additionally, it showed that the
individual symptoms that were significantly more sensitive
to the oral iron treatment were heartburn, abdominal pain
and the presence of black stools. Although there has been
concern that black stools caused by oral iron may mask
black stools caused by gastrointestinal blood loss, it is not
per se an adverse-effect related to symptoms but, rather, it
represents the formation of iron sulphide in the colon due
to bacterial activity. However, it could be useful as a marker
of the change in bacterial flora (i.e. an increase in sulphate-
reducing bacteria at the expense of beneficial bacterial
genus such as lactobacilli) in future intervention studies
with oral iron and this could be further investigated.
Despite the uncomplicated format of the questionnaire,
a large amount of data is generated. For example, in this
small study, 20 participants provided 14 days of question-
naire each (i.e. 280 questionnaires) with 28 pieces of infor-
mation per questionnaire: this represents 7,840 pieces of
data recorded, for most, in a categorical format, for some
in a binary form, and for others in a continuous format.
To facilitate analysis, the main outcomes were restricted
to binary events (e.g. presence and absence of symptoms),
and the categorisation of their severity was only focussed
on data collected from boxes C, H and I of the question-
naire. Clearly, in future studies that utilise this question-
naire, researchers will need to determine whether (a) they
collect all data or simplify the questionnaire even furtherso that only C, H and I are used and (b) if they collect all,
how it should be best analysed.
Finally, whether the whole questionnaire (Figure 1) is
used, or a short version with only boxes C, H and I, a
comments box may be a useful addition for patients/
participants to provide detail that may inform upon
their responses.
Competing interests
The authors declare no conflict of interest but DIAP and JJP wish to note that
they are co-inventors on a patent detailing novel Fe(III) poly oxo-hydroxide
structures that may have potential as dietary supplements and that they consult
to Iron Therapeutics UK Limited for advice on their novel oral iron therapeutic.
Authors’ contributions
MCEL and JJP designed the research; MCEL conducted the research; DIAP
and SMI analysed data; DIAP, SMI and JJP wrote the paper; DIAP and JJP had
primary responsibility for final content. All authors read and approved the
final manuscript.
Acknowledgements
We thank Natasha Vidas for her assistance with the human study. The
authors would like to thank the UK Medical Research Council (MRC)
(U105960399), for funding part of this work. This work is a publication of the
UK Medical Research Council.
Author details
1MRC Human Nutrition Research, Elsie Widdowson Laboratory, CB1 9NL
Cambridge, UK. 2Diabetes and Nutritional Sciences Division, King’s College
London, London, UK.
Received: 10 December 2013 Accepted: 29 May 2014
Published: 4 June 2014
References
1. WHO: The Global Burden of Disease: 2004 Update. Geneva: WHO; 2008:1–146.
2. WHO: The World Health Report. Reducing Risks, Promoting Healthy Life.
Geneva: WHO; 2002.
3. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ: Selected major
risk factors and global and regional burden of disease. Lancet 2002,
360:1347–1360.
4. Joint Formulary Committee: British National Formulary. London: British
Medical Association: Pharmaceutical Society of Great Britain; 2014.
5. de Souza AI, Batista Filho M, Bresani CC, Ferreira LO, Figueiroa JN:
Adherence and side effects of three ferrous sulfate treatment regimens
on anemic pregnant women in clinical trials. Cad Saude Publica 2009,
25:1225–1233.
6. Milman N, Byg KE, Bergholt T, Eriksen L: Side effects of oral iron prophylaxis
in pregnancy–myth or reality? Acta Haematol 2006, 115:53–57.
7. Galloway R, McGuire J: Determinants of compliance with iron
supplementation: supplies, side effects, or psychology? Soc Sci Med 1994,
39:381–390.
8. de Silva AD, Tsironi E, Feakins RM, Rampton DS: Efficacy and tolerability of
oral iron therapy in inflammatory bowel disease: a prospective,
comparative trial. Aliment Pharmacol Ther 2005, 22:1097–1105.
9. Idoate Gastearena MA, Gil AG, Azqueta A, Coronel MP, Gimeno M: A
comparative study on the gastroduodenal tolerance of different
antianaemic preparations. Hum Exp Toxicol 2003, 22:137–141.
10. Mohamed HJ, Vidas N, Mudway IS, Liu DY, Geissler CA, Powell JJ, Lomer MC: Oral
ferrous sulphate tolerance study in healthy individuals (Poster). In TEMA 12
Symposium. Northern Ireland, UK: University of Ulster at Coleraine; 2005.
11. Sazawal S, Black RE, Ramsan M, Chwaya HM, Stoltzfus RJ, Dutta A, Dhingra U,
Kabole I, Deb S, Othman MK, Kabole FM: Effects of routine prophylactic
supplementation with iron and folic acid on admission to hospital and
mortality in preschool children in a high malaria transmission setting:
community-based, randomised, placebo-controlled trial. Lancet 2006,
367:133–143.
12. Drakesmith H, Prentice A: Viral infection and iron metabolism. Nat Rev
Microbiol 2008, 6:541–552.
Pereira et al. BMC Gastroenterology 2014, 14:103 Page 7 of 8
http://www.biomedcentral.com/1471-230X/14/10313. Friedman JF, Kurtis JD, Kabyemela ER, Fried M, Duffy PE: The iron trap: iron,
malaria and anemia at the mother-child interface. Microbes Infect 2009,
11:460–466.
14. WHO: Conclusions and recommendations of the WHO Consultation on
prevention and control of iron deficiency in infants and young children
in malaria-endemic areas. Food Nutr Bull 2007, 28:S621–S627.
15. GP prescribing data. [http://www.hscic.gov.uk/gpprescribingdata]
16. Ruivard M, Feillet-Coudray C, Rambeau M, Gerbaud L, Mazur A, Rayssiguier Y,
Philippe P, Coudray C: Effect of daily versus twice weekly long-term iron sup-
plementation on iron absorption and status in iron-deficient women: a
stable isotope study. Clin Biochem 2006, 39:700–707.
17. Siddiqui IA, Rahman MA, Jaleel A: Efficacy of daily vs. weekly
supplementation of iron in schoolchildren with low iron status. J Trop
Pediatr 2004, 50:276–278.
18. Fischer Walker CL, Baqui AH, Ahmed S, Zaman K, El Arifeen S, Begum N,
Yunus M, Black RE, Caulfield LE: Low-dose weekly supplementation of iron
and/or zinc does not affect growth among Bangladeshi infants. Eur J Clin
Nutr 2009, 63:87–92.
19. Hyder SM, Persson LA, Chowdhury AM, Ekstrom EC: Do side-effects reduce
compliance to iron supplementation? A study of daily- and weekly-dose
regimens in pregnancy. J Health Popul Nutr 2002, 20:175–179.
20. Stoltzfus RJ, Chway HM, Montresor A, Tielsch JM, Jape JK, Albonico M,
Savioli L: Low dose daily iron supplementation improves iron status and
appetite but not anemia, whereas quarterly anthelminthic treatment
improves growth, appetite and anemia in Zanzibari preschool children.
J Nutr 2004, 134:348–356.
21. Makrides M, Crowther CA, Gibson RA, Gibson RS, Skeaff CM: Efficacy and
tolerability of low-dose iron supplements during pregnancy: a random-
ized controlled trial. Am J Clin Nutr 2003, 78:145–153.
22. Shatrugna V, Raman L, Kailash U, Balakrishna N, Rao KV: Effect of dose and
formulation on iron tolerance in pregnancy. Natl Med J India 1999, 12:18–20.
23. Little BB: Pharmacokinetics during pregnancy: evidence-based maternal
dose formulation. Obstet Gynecol 1999, 93:858–868.
24. Hutchinson C, Al-Ashgar W, Liu DY, Hider RC, Powell JJ, Geissler CA: Oral
ferrous sulphate leads to a marked increase in pro-oxidant
nontransferrin-bound iron. Eur J Clin Invest 2004, 34:782–784.
25. Erichsen K, Ulvik RJ, Grimstad T, Berstad A, Berge RK, Hausken T: Effects of
ferrous sulphate and non-ionic iron-polymaltose complex on markers of
oxidative tissue damage in patients with inflammatory bowel disease.
Aliment Pharmacol Ther 2005, 22:831–838.
26. Evans P, Halliwell B: Micronutrients: oxidant/antioxidant status. Br J Nutr
2001, 85(Suppl 2):S67–S74.
27. Dostal A, Chassard C, Hilty FM, Zimmermann MB, Jaeggi T, Rossi S, Lacroix C:
Iron depletion and repletion with ferrous sulfate or electrolytic iron
modifies the composition and metabolic activity of the gut microbiota in
rats. J Nutr 2012, 142:271–277.
28. Werner T, Wagner SJ, Martinez I, Walter J, Chang JS, Clavel T, Kisling S,
Schuemann K, Haller D: Depletion of luminal iron alters the gut
microbiota and prevents Crohn’s disease-like ileitis. Gut 2011, 60:325–333.
29. Zimmermann MB, Chassard C, Rohner F, N’Goran EK, Nindjin C, Dostal A,
Utzinger J, Ghattas H, Lacroix C, Hurrell RF: The effects of iron fortification
on the gut microbiota in African children: a randomized controlled trial
in Cote d’Ivoire. Am J Clin Nutr 2010, 92:1406–1415.
30. Crane SJ, Talley NJ: Chronic gastrointestinal symptoms in the elderly.
Clin Geriatr Med 2007, 23:721–734. v.
31. Kearney DJ, McDermott K, Martinez M, Simpson TL: Association of
participation in a mindfulness programme with bowel symptoms,
gastrointestinal symptom-specific anxiety and quality of life.
Aliment Pharmacol Ther 2011, 34:363–373.
32. Jerndal P, Ringstrom G, Agerforz P, Karpefors M, Akkermans LM, Bayati A,
Simren M: Gastrointestinal-specific anxiety: an important factor for
severity of GI symptoms and quality of life in IBS. Neurogastroenterol Motil
2010, 22:646–e179.
33. Portincasa P, Maggipinto A, Berardino M, Bonfrate L, Costin S, Todarello O,
Palasciano G, Wang DQ, Dumitrascu DL: Assessing gastrointestinal
symptoms and perception, quality of life, motility, and autonomic
neuropathy in clinical studies. J Gastrointestin Liver Dis 2009, 18:205–211.
34. Jeong JJ, Choi MG, Cho YS, Lee SG, Oh JH, Park JM, Cho YK, Lee IS, Kim SW,
Han SW, Choi KY, Chung IS: Chronic gastrointestinal symptoms and
quality of life in the Korean population. World J Gastroenterol 2008,
14:6388–6394.35. Brunner HI, Johnson AL, Barron AC, Passo MH, Griffin TA, Graham TB,
Lovell DJ: Gastrointestinal symptoms and their association with health-
related quality of life of children with juvenile rheumatoid arthritis: val-
idation of a gastrointestinal symptom questionnaire. J Clin Rheumatol
2005, 11:194–204.
36. Bovenschen HJ, Laheij RJ, Tan AC, Witteman EM, Rossum LG, Jansen JB:
Health-related quality of life of patients with gastrointestinal symptoms.
Aliment Pharmacol Ther 2004, 20:311–319.
37. Wolfe F, Kong SX, Watson DJ: Gastrointestinal symptoms and health related
quality of life in patients with arthritis. J Rheumatol 2000, 27:1373–1378.
38. Schultink W, van der Ree M, Matulessi P, Gross R: Low compliance with an
iron-supplementation program: a study among pregnant women in
Jakarta, Indonesia. Am J Clin Nutr 1993, 57:135–139.
39. Lutsey PL, Dawe D, Villate E, Valencia S, Lopez O: Iron supplementation
compliance among pregnant women in Bicol, Philippines. Public Health
Nutr 2008, 11:76–82.
40. Seck BC, Jackson RT: Determinants of compliance with iron supplementation
among pregnant women in Senegal. Public Health Nutr 2008, 11:596–605.
41. Armstrong D, Veldhuyzen SJ, Chung SA, Shapiro CM, Dhillon S, Escobedo S,
Chakraborty BK, Mann V, Tanser L, Nevin K: Validation of a short
questionnaire in English and French for use in patients with persistent
upper gastrointestinal symptoms despite proton pump inhibitor
therapy: the PASS (Proton pump inhibitor Acid Suppression Symptom)
test. Can J Gastroenterol 2005, 19:350–358.
42. Dimenas E, Carlsson G, Glise H, Israelsson B, Wiklund I: Relevance of norm
values as part of the documentation of quality of life instruments for
use in upper gastrointestinal disease. Scand J Gastroenterol 1996, 31:8–13.
43. Dimenas E, Glise H, Hallerback B, Hernqvist H, Svedlund J, Wiklund I: Well-
being and gastrointestinal symptoms among patients referred to
endoscopy owing to suspected duodenal-ulcer. Scand J Gastroenterol
1995, 30:1046–1052.
44. Talley NJ, Boyce PM, Owen BK, Newman P, Paterson KJ: Initial validation of a
bowel symptom questionnaire and measurement of chronic
gastrointestinal symptoms in Australians. Aust N Z J Med 1995, 25:302–308.
45. Foster JM, van der Molen T, Caeser M, Hannaford P: The use of
questionnaires for measuring patient-reported side effects of drugs: its
importance and methodological challenges. Pharmacoepidemiol Drug Saf
2008, 17:278–296.
46. Varma MG, Wang JY, Berian JR, Patterson TR, McCrea GL, Hart SL: The
constipation severity instrument: a validated measure. Dis Colon Rectum
2008, 51:162–172.
47. Quan C, Talley NJ, Cross S, Jones M, Hammer J, Giles N, Horowitz M:
Development and validation of the diabetes bowel symptom
questionnaire. Aliment Pharmacol Ther 2003, 17:1179–1187.
48. Nappi CTG, Morra I, Massaro M, Formisano C, Di Carlo C: Efficacy and
tolerability of oral bovine lactoferrin compared to ferrous sulfate in
pregnant women with iron deficiency anemia: a prospective
controlled randomized study. Acta Obstet Gynecol Scand 2009,
88:1031–1035.
49. Sifakis S, Angelakis E, Papadopoulou E, Stratoudakis G, Fragouli Y,
Koumantakis E: The efficacy and tolerability of iron protein succinylate in
the treatment of iron-deficiency anemia in pregnancy. Clin Exp Obstet
Gynecol 2005, 32:117–122.
50. Aamodt AH, Stovner LJ, Hagen K, Zwart JA: Comorbidity of headache and
gastrointestinal complaints. The Head-HUNT Study. Cephalalgia 2008,
28:144–151.
51. Spierings EL: Headache of gastrointestinal origin: case studies.
Headache 2002, 42:217–219.
52. Pedersen A, Sandstrom B, Van Amelsvoort JM: The effect of ingestion of
inulin on blood lipids and gastrointestinal symptoms in healthy females.
Br J Nutr 1997, 78:215–222.
53. Carrier J, Aghdassi E, Cullen J, Allard JP: Iron supplementation increases
disease activity and vitamin E ameliorates the effect in rats with dextran
sulfate sodium-induced colitis. J Nutr 2002, 132:3146–3150.
54. Lund EK, Wharf SG, Fairweather-Tait SJ, Johnson IT: Oral ferrous sulfate sup-
plements increase the free radical-generating capacity of feces from
healthy volunteers. Am J Clin Nutr 1999, 69:250–255.
55. Orozco MN, Solomons NW, Schumann K, Friel JK, de Montenegro AL:
Antioxidant-rich oral supplements attenuate the effects of oral iron
on in situ oxidation susceptibility of human feces. J Nutr 2010,
140:1105–1110.
Pereira et al. BMC Gastroenterology 2014, 14:103 Page 8 of 8
http://www.biomedcentral.com/1471-230X/14/10356. Kortman GA, Boleij A, Swinkels DW, Tjalsma H: Iron availability increases
the pathogenic potential of Salmonella typhimurium and other
enteric pathogens at the intestinal epithelial interface. PLoS One 2012,
7:e29968.
57. Gibson GR: Physiology and ecology of the sulphate-reducing bacteria.
J Appl Bacteriol 1990, 69:769–797.
doi:10.1186/1471-230X-14-103
Cite this article as: Pereira et al.: A rapid, simple questionnaire to assess
gastrointestinal symptoms after oral ferrous sulphate supplementation.
BMC Gastroenterology 2014 14:103.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
